Vir Biotechnology EBIT

Vir Biotechnology (VIR) currently reports a EBIT of $-270M as of June 2026. That compares with $-590M in the prior-year period — up 54.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Vir Biotechnology's EBIT history and peer comparisons.

Vir Biotechnology's EBIT increased from $-590M to $-270M — a 54.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vir Biotechnology's EBIT of $-270M is lower than the Healthcare sector average of $23B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Vir Biotechnology reported $-270M in EBIT as of June 2026. That compares with $-590M in the prior-year period — up 54.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-270M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Vir Biotechnology, and consider following VIR for alerts when major investors trade the stock.